Globeflex Capital’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.38M Buy
74,576
+68,812
+1,194% +$2.89M 0.56% 60
2026
Q1
$186K Hold
5,764
0.03% 307
2025
Q4
$243K Hold
5,764
0.04% 281
2025
Q3
$198K Buy
+5,764
New +$165K 0.03% 294
2025
Q2
Sell
-9,304
Closed -$276K 464
2025
Q1
$276K Hold
9,304
0.03% 295
2024
Q4
$368K Hold
9,304
0.03% 292
2024
Q3
$317K Buy
+9,304
New +$262K 0.03% 292
2023
Q2
Sell
-11,950
Closed -$266K 513
2023
Q1
$266K Buy
11,950
+5,550
+87% +$134K 0.03% 320
2022
Q4
$152K Buy
+6,400
New +$149K 0.02% 358

Other funds holding VCYT

Globeflex Capital's VCYT Position: Q2 2026 in Review

Globeflex Capital increased its Veracyte (VCYT) stake by 1,194% in Q2 2026, buying an estimated $2.89M and bringing the position to 74,576 shares worth $4.38M. The position accounts for 0.56% of the portfolio, ranked #60.

Globeflex Capital first reported a position in VCYT in Q4 2022 and has held it in 9 quarters since. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Globeflex Capital held 74,576 shares of Veracyte worth $4.38M as of Q2 2026.
  • Globeflex Capital bought 68,812 Veracyte shares in Q2 2026, an estimated $2.89M.
  • Veracyte made up 0.56% of Globeflex Capital's portfolio in Q2 2026, its #60 holding.
  • Globeflex Capital first reported a position in Veracyte in Q4 2022 and has held it in 9 quarters since.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.